| Literature DB >> 29944162 |
Laila Santos de Andrade1, Maria Aparecida Dalboni2, José Tarcisio Giffoni de Carvalho2, Caren Cristina Grabulosa2, Natalia Barros Ferreira Pereira2, Danilo Takashi Aoike2, Lilian Cuppari1,2.
Abstract
INTRODUCTION: In chronic kidney disease (CKD), it has been suggested that alterations within the gut are associated with an inflammatory state and uremic toxicity. Studies suggest that uremia may impair the function of the intestinal barrier via the promotion of increased intestinal permeability. To understand the mechanisms that are involved in intestinal barrier damage in the setting of uremia, we evaluated the in vitro effect of uremic serum on transepithelial electrical resistance (TER), inflammation, and apoptosis in intestinal epithelial cells (T84).Entities:
Mesh:
Year: 2018 PMID: 29944162 PMCID: PMC6533953 DOI: 10.1590/2175-8239-jbn-3949
Source DB: PubMed Journal: J Bras Nefrol ISSN: 0101-2800
Demographic data from patients included in each pool and laboratory data from each pool of serum that was used in the study
| Variables | CTL | NDD-CKD | Pre-HD | Post-HD |
|---|---|---|---|---|
| Age (years) | 31.4 ± 8.98 | 57.4 ± 11.43 | 58 ± 9.67 | - |
| Male [n (%)] | 2 (40) | 3 (60) | 1 (20) | - |
| Creatinine (mg/dL) | 0.82 | 2.9 | 11.54 | 3.33 |
| Urea (mg/dL) | 33 | 108 | 149 | 32.0 |
| PTH (pg/mL) | 23 | 161 | 763 | 381 |
| Calcium (mg/dL) | 9.7 | 9.2 | 9.0 | 10.5 |
| Phosphorus (mg/dL) | 3.4 | 4.1 | 4.8 | 2.3 |
| Potassium (mEq/L) | 3.8 | 4.7 | 4.8 | 2.8 |
Serum pool: CTL- healthy control; NDD-CKD- non-dialysis-dependent chronic kidney disease; HD- hemodialysis; PTH-parathyroid hormone.
Figure 1Transepithelial electrical resistance (TER) across the monolayer of T84 cells, after incubation under the different conditions. Data are presented as mean ± SE. p > 0.05 between groups. Serum pool: CTL- healthy control; NDD-CKD-non-dialysis-dependent chronic kidney disease; HD- hemodialysis.
Expression of TLR-2, TLR-4, and TLR-9 and production of ROS and IL-6 in T84 cells
| Variables | CTL | NDD-CKD | Pre-HD | Post-HD |
|
|---|---|---|---|---|---|
| TLR-2 (MFI) | 10,227 ± 2,653 | 10,391 ± 3,266 | 11,826 ± 3,422 | 14,940 ± 9,032 | 0.493 |
| TLR-2 (%) | 94.6 (89.9-96.9) | 93.3 (85.1-97.7) | 94 (88.4-98.2) | 94.8 (87.2-96.8) | 0.827 |
| TLR-4 (MFI) | 6,030 (5,537-8,727) | 6,504 (5,609-8,364) | 7,668 (6,263-9,834) | 9,119 (5,743-15,812) | 0.418 |
| TLR-4 (%) | 82.6 (76.2-91) | 80.6 (76-92.5) | 82 (77.2-93.4) | 84.9 (78.8-91) | 0.851 |
| TLR-9 (MFI) | 3,773 (2,149-9,303) | 2,995 (2,115-12,856) | 2,789 (2,111-7,273) | 3,580 (2,980-8,425) | 0.937 |
| TLR-9 (%) | 4.8 (1.15-7.7) | 4.6 (1.07-8.72) | 4.15 (0.82-6.8) | 4.45 (1.15-8.65) | 0.971 |
| ROS (MFI) | 293.4 ± 72.7 | 289.2 ± 54.83 | 291 ± 65.2 | 294.6 ± 44.8 | 0.999 |
| ROS (%) | 40.8 (34.5-65.7) | 46.2 (35.9-62.8) | 38.4 (32.3-57.5) | 33.6 (25.3-50.5) | 0.628 |
| IL-6 (pg/mL) | 0.76 ± 0.35 | 1.14 ± 0.53 | 2.27 ± 0.46* | 2.85 ± 0.93*† | < 0.001 |
Data are presented as mean ± SD or as the median (interquartile range). *p < 0.01 vs. CTL and NDD-CKD; † p = 0.07 vs. Pre-HD. MFI- Mean fluorescence intensity; TLR-2- Toll-like receptor 2; TLR-4- Toll-like receptor 4; TLR-9- Toll-like receptor 9; IL-6- Interleukin-6. Serum pool: CTL- healthy control; NDD-CKD- non-dialysis-dependent chronic kidney disease; HD- hemodialysis.
Figure 2Illustration of the strategy performed to detect the expression of the toll-like receptors, production of ROS, and apoptosis by flow cytometry. (A) Forward and side scatters were used to gate T84 cells and to exclude cellular debris. (B) Example of Toll-like receptor 4 (TLR-4) expression in each condition of incubation. CTL- healthy control; NND-CKD- non-dialysis-dependent chronic kidney disease; HD- hemodialysis. TLR-4- Toll-like receptor 4.
Figure 3Production of IL-6 by T84 cells after incubation under the different conditions. Data are presented as mean (95% CI). * p < 0.01 vs. CTL and NDD-CKD. Serum pool: CTL- healthy control; NND-CKD-non-dialysis-dependent chronic kidney disease; HD- hemodialysis.
Viability, apoptosis and cell necrosis
| Variables | CTL | NDD-CKD | Pre-HD | Post-HD |
|
|---|---|---|---|---|---|
| Viability (%) | 80.5 ± 5.2 | 82.9 ± 4.35 | 82.7 ± 4.8 | 82.1 ± 3.7 | 0.841 |
| Early apoptosis (%) | 6.8 ± 2.35 | 5.8 ± 1.6 | 5.5 ± 1.95 | 6.2 ± 2.3 | 0.751 |
| Late apoptosis (%) | 6.5 (6.1-8.4) | 6.3 (5.4-7.4) | 6.5 (5.7-7.4) | 6.4 (6.0-8.3) | 0.755 |
| Necrosis (%) | 4.6 (2.7-9.1) | 3.3 (2.1-8.7) | 3.9 (1.8-9.9) | 5.0 (2.3-7.0) | 0.984 |
Data are presented as the mean ± SD or as the median (interquartile range). p > 0.05 between groups. Serum pool: CTL- healthy control; NDD-CKD- non-dialysis-dependent chronic kidney disease; HD- hemodialysis.